Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00043966
Status:
COMPLETED
Last Update Posted:
2006-07-27
First Post:
2002-08-15
Brief Title:
Study of Lopinavir Ritonavir Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
A Randomized Open-Label Study of 800 Mg Lopinavir200 Mg Ritonavir QD in Combination With Tenofovir and Emtricitabine Vs 400 Mg Lopinavir 100 Mg Ritonavir BID in Combination With Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects
Status:
COMPLETED
Status Verified Date:
2006-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the safety tolerability and antiviral activity between once-daily QD and twice-daily BID dosing of lopinavirritonavir and to further characterize the pharmacokinetics of once-daily dosing of lopinavirritonavir
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None